Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 20, 2007, Pages 5537-5542

  Kawai, Makoto ^a   Sakurada, Isao ^a   Morita, Asato ^a   Iwamuro, Yuko ^a   Ando, Kazuo ^a   Omura, Hirofumi ^a   Sakakibara, Sachiko ^a   Masuda, Tsutomu ^a   Koike, Hiroki ^a   Honma, Teruki ^a   Hattori, Kazunari ^a   Takashima, Tadayuki ^a   Mizuno, Kunihiko ^a   Mizutani, Mayumi ^a   Kawamura, Mitsuhiro ^a  

^a PFIZER INC   (United States)

Author keywords

Bioactivation; Metabolic stability; NMDA; NR2B; Reactive metabolite

Indexed keywords

AROMATIC AMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG STABILITY; DRUG STRUCTURE; LIVER MICROSOME; MOUSE; NONHUMAN; PKA; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; CELL LINE; GLUTATHIONE; HUMANS; MICE; MOLECULAR STRUCTURE; NEURONS; PHENOL; PHENOLS; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548602403     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.033     Document Type: Article

References (14)

1. Parsons C.G., Danysz W., and Quack G. Drug News Perspect. 11 (1998) 523
2. Knox D.J., McLeod B.J., and Goucke C.R. Anaesth Intensive Care 23 (1995) 620
3. Ilkjaer S., Dirks J., Brennum J., Wernberg M., and Dahl J.B. Br. J. Anaesth. 79 (1997) 600
4. McCartney, C. J. L.; Sinha, A.; Katz, J. Anesthesia & Analgesia (Hagerstown, MD, United States) 2004, 98, 1385.
5. Nelson K.A., Park K.M., Robinovitz E., Tsigos C., and Max M.B. Neurology 48 (1997) 1212
6. Sang C.N.W.J.J., Jinga L., Wouden J., and Saltarelli M.D. Soc. Neurosci. Abstr. (2003) 814
7. Kawai, M. Bioorg. Med. Chem. Lett., in press, Discovery of novel and orally active NR2B-selective N-methyl d-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
8. Kawai, M.; Kawamura, M.; Sakurada, I.; Morita, A.; (Pfizer Japan, Inc., Japan; Pfizer Inc.). WO2005080317; p. 213 pp.
9. Evans D.C., Watt A.P., Nicoll-Griffith D.A., and Baillie T.A. Chem. Res. Toxicol. 17 (2004) 3
10. Kalgutkar A.S., Gardner I., Obach R.S., Shaffer C.L., Callegari E., Henne K.R., Mutlib A.E., Dalvie D.K., Lee J.S., Nakai Y., O'Donnell J.P., Boer J., and Harriman S.P. Curr. Drug Metabol. 6 (2005) 161
11. Chen W.G., Zhang C., Avery M.J., and Fouda H.G. Adv. Exp. Med. Biol. 500 (2001) 521
12. Pigou P.E. J. Org. Chem. 54 (1989) 4943
13. 2: C, 69.70; H, 7.70; N, 12.83. Found: C, 69.34; H, 7.60; N, 12.72; mp 155.7 °C.
14. Rietjens I.M.C.M., Cnubben N.H.P., van Haandel M., Tyrakowska B., Soffers A.E.M.F., and Vervoort J. Chem. Biol. Interact. 94 (1995) 49